Results 251 to 260 of about 84,264 (300)
Some of the next articles are maybe not open access.
Phosphodiesterase-5 Inhibitors
2013Nitric oxide (NO) signaling plays a key role in modulating vascular tone and remodeling in the pulmonary circulation. The guanylate cyclase/cyclic guanylate monophosphate-signaling pathway primarily mediates nitric oxide signaling. This pathway is critical in normal regulation of the pulmonary vasculature, and is an important target for therapy in ...
Barbara A, Cockrill, Aaron B, Waxman
openaire +2 more sources
Phosphodiesterase inhibitors and lung diseases
2023Phosphodiesterase enzymes (PDE) have long been known as regulators of cAMP and cGMP, second messengers involved in various signaling pathways and expressed in a variety of cell types implicated in respiratory diseases such as airway smooth muscle and inflammatory cells making them a key target for the treatment of lung diseases as chronic obstructive ...
Ivana, Stolfa, Clive, Page
openaire +2 more sources
Phosphodiesterase inhibitors in psychiatric disorders
Psychopharmacology, 2023Challenges in drug development for psychiatric disorders have left much room for the introduction of novel treatments with better therapeutic efficacies and indices. As a result, intense research has focused on identifying new targets for developing such pharmacotherapies.
Mohammad Amin, Sadeghi +5 more
openaire +2 more sources
Chemotherapeutic potential of phosphodiesterase inhibitors
Current Opinion in Chemical Biology, 1998The application of molecular cloning has revealed the phenomenal diversity and complexity of the phosphodiesterase isoenzyme family. Thus, more than 30 human phosphodiesterases are now known; all are apparently necessary for the seemingly simple task of hydrolysing the 3'-ester bond of either cyclic adenosine monophosphate or cyclic guanosine ...
M J, Perry, G A, Higgs
openaire +2 more sources
2021
Cerebral ischemic diseases are among the most prevalent causes of death and the leading cause of adult disability worldwide. Although many studies have investigated the pathophysiological mechanisms involved in the cerebral ischemic injury, no effective pharmacological treatment has been established.
openaire +1 more source
Cerebral ischemic diseases are among the most prevalent causes of death and the leading cause of adult disability worldwide. Although many studies have investigated the pathophysiological mechanisms involved in the cerebral ischemic injury, no effective pharmacological treatment has been established.
openaire +1 more source
The new inotropic phosphodiesterase inhibitors
Archives Internationales de Physiologie et de Biochimie, 1984Compounds with phosphodiesterase inhibitory activity stimulate myocardial contractility by increasing the intracellular cyclic AMP concentrations. They can also increase Ca2+ entry and inhibit Ca2+ sequestration by the sarcoplasmic reticulum. Xanthines produce bronchodilation with associated venous and arteriolar dilation. However, their use is limited
D, el Allaf, V, D'Orio, J, Carlier
openaire +2 more sources
Phosphodiesterase inhibitors in clinical urology
Expert Review of Clinical Pharmacology, 2013To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic hyperplasia and symptoms of female sexual dysfunction (including arousal and orgasmic disorders), can be therapeutically approached by influencing the ...
Stefan, Ückert +2 more
openaire +2 more sources
Phosphodiesterase Inhibitors: History of Pharmacology
2011The first pharmacological investigations of phosphodiesterase (PDE) inhibitors were developed with the clinical efficacies of drugs isolated from coffee, cacao and tea but only later their relevant ingredients were identified as xanthines that act as PDE.
Christian, Schudt +3 more
openaire +2 more sources
Phosphodiesterase Inhibitors for Cognitive Enhancement
Current Pharmaceutical Design, 2005An effective treatment for age-related cognitive deficits remains an unmet medical need. Currently available drugs for the symptomatic treatment of Alzheimer's disease or other dementias have limited efficacy. This may be due to their action at only one of the many neurotransmitter systems involved in the complex mechanisms that underlie cognition.
Gregory M, Rose +3 more
openaire +2 more sources
Inhibitors of phosphodiesterases in the treatment of cough
Respiratory Physiology & Neurobiology, 2018A group of 11 enzyme families of metalophosphohydrolases called phosphodiesterases (PDEs) is responsible for a hydrolysis of intracellular cAMP and cGMP. Xanthine derivatives (methylxanthines) inhibit PDEs without selective action on their single isoforms and lead to many pharmacological effects, e.g.
Juraj, Mokry +3 more
openaire +2 more sources